STREPTOCOCCUS MUTANS - POSSIBLE RISK FACTOR FOR ANTIBIOTIC RESISTANCE PREVALENCE

Abstract

Aim. To assess the prevalence of erythromycin and tetracycline-resistant S.mutans strains, isolated from child dental deposit; to determine the leading mechanism of their resistance to microlides. Materials and methods. Eighty six S. mutans strains, isolated from the dental deposits of children aged 6-17 years were studied. Screening of erythromycin resistance was fulfilled with two methods - phenotypical and genotypical, tetracycline - with phenotypical alone. Results. The share of S. mutans isolates, phenotypically resistant to erythromycin, was 16 % , to tetracycline - 26,7 %. The prevailing molecular-genetic mechanism of erythromycin resistance - presence of mef A-gene (78,6 % of all erythromycin-resistant strains); 10,5 % of all the studied S. mutans strains is a potential reservoir of antibiotic resistance genes ( erm B and mef A) in the horizontal transmission.

Keywords

S. mutans / Viridans Streptococci / erm B / mef A / S. mutans / Viridans Streptococci / antibiotic resistance genes / erm B and mef A

References

[1] Bruckner L., Gigliotti F. Viridans group streptococcal infections among children with cancer and the importance of emerging antibiotic resistance. Semin Pediatr Infect Dis 2006; 17: 153-160.

[2] Balletto E., Mikulska M. Bacterial infections in hematopoietic stem cell transplant recipients. Mediterr J Hematol Infect Dis 2015; 7: 101-109.

[3] Douglas C. Identity of viridans streptococci isolated from cases of infective endocarditis. J Med Microbiol 1993; 39: 179-182.

[4] Gordon, K.A., Beach M.L., Biedenbach D.J., Jones R.N., Rhomberg P.R., Mutnick A.H. Antimicrobial susceptibility patterns of hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diag Microbiol Infect Dis 2002; 43: 157-162.

[5] Ioannidou S., Papaparaskevas J., Tas-sios P.T., Foustoukou M., Legakis N.J., Vatopoulus A. Prevalence and characterization of the mechanisms of macrolide, lincosamide and streptogramin resistance in viridans group streptococci. Int J Antimicrob Agents 2003; 22: 626-629.

[6] Kennedy H.F., Gemmell C.G., Bagg J., Gibson B.E.S., Michie J.R. Antimicrobial susceptibility of blood culture isolates of viridans group streptococci: relationship to a change in empirical antibiotic therapy in febrile neutropenia. J Antimicrob Chemother 2001; 47: 693-696.

[7] Luna V.A., Coates P., Eady E.A., Cove J.H., Nguyen T.T., Roberts M.C. A variety of gram-positive bacteria carry mobile mef genes. J Antimicrob Chemother 1999; 44: 19-25.

[8] National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing - Thirteenth Informational Supplement M100-S13. NCCLS, Wayne, PA, USA 2003.

[9] Seppala H., Haanpera M., Al-Juhaish M., Jarvinen H., Jalava J., Huovinen J. Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J Antimicrob Chemother 2003; 52: 636-644.

[10] Seppala H., Nissinen A., Yu Q., Huovinen P. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother 1993; 32: 885-891.

[11] Seppala H., Skurnik M., Soini H., Roberts M.C., Huovinen P. A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob Agents Chemother 1998; 42: 257-262.

[12] Soriano F., Rodriguez-Cerrato V. Pharmacodynamic and kinetic basis for the selection of pneumococcal resistance in the upper respiratory tract. Journal of Antimicrobial Chemotherapy 2002; 50: 51-58.

RIGHTS & PERMISSIONS

Brodina T.V., Lyubimova A.V., Feting A.E., Silin A.V., Yusupova R.F., Kiselev A.V., Klimova E.A.